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Objective: N-acetylcysteine (NAC) is beneficial in psychiatric conditions, including schizophrenia.
Patients with schizophrenia exhibit mesolimbic dopamine hyperfunction consequent to an endogenous
sensitization process. This sensitization can be modeled in rodents by repeated exposure to psycho-
stimulants, provoking an enduring amplified response at subsequent exposure. The aim of this study
was to investigate the effects of NAC on amphetamine sensitization in mice.
Methods: D-amphetamine was administered to C57BL/6 mice three times a week for 3 weeks; the
dose was increased weekly from 1 to 3 mg/kg. NAC (60 mg/kg) or saline was administered intra-
peritoneally before saline or amphetamine during the second and third weeks. After a 4-week washout
period, latent inhibition (LI) and the locomotor response to amphetamine 2 mg/kg were assessed.
Results: Sensitization disrupted LI and amplified the locomotor response; NAC disrupted LI in control
mice. In sensitized animals, NAC attenuated the enhanced locomotion but failed to prevent LI disruption.
Conclusion: NAC warrants consideration as a candidate for early intervention in ultra-high risk subjects
due to its safety profile and the relevance of its mechanism of action. Supplementing this proposition,
we report that NAC attenuates sensitization-induced locomotor enhancement in mice. The finding that
NAC disrupted LI incites a cautionary note and requires clarification.
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Introduction
The long-standing dopamine hypothesis of schizophrenia
postulates that mesolimbic dopamine hyperfunction under-
lies the psychotic symptoms of the disorder. This dopamine
hyperfunction is considered the result of an ‘‘endogenous
sensitization’’ process,1,2 matching neuroimaging studies
that show enhanced striatal dopamine release in response
to acute amphetamine challenge in patients with schizo-
phrenia.3,4 Moreover, repeated consumption of high doses
of amphetamine (or other stimulants) often results in the
progressive development of a psychotic state that closely
resembles paranoid schizophrenia.5,6
The amplified sensitivity to amphetamine seen in patients
with schizophrenia can be recapitulated in rodents by repeated
exposure to psychostimulants, a sensitization process lead-
ing to increased response to a later exposure to the same
drug. Animals sensitized to amphetamine display enhanced
response to the drug even months or years after its
withdrawal, illustrating this is an enduring phenomenon.7
Because amphetamine sensitization induces behavioral and
neurochemical abnormalities similar to those observed in
schizophrenia, it has become a widely accepted animal
model of the disorder.8,9
N-acetylcysteine (NAC) is a safe and well-tolerated drug,
clinically used as a mucolytic and antidote against para-
cetamol toxicity.10,11 NAC is a glutathione precursor that
exerts antioxidant, anti-inflammatory, anti-apoptotic and
neurotrophic actions.12-14 NAC also modulates glutamate
release through activation of the cystine-glutamate anti-
porter expressed in astrocytes at extra-synaptic sites.15,16
The effects of this promising drug in psychiatry17 were
assessed in several clinical trials,18 which demonstrated
the beneficial effect of NAC as an adjunctive treatment for
neuropsychiatric disorders.
The purpose of this study was to investigate the effects
of NAC on amphetamine sensitization. We used an esca-
lating dose protocol that induces hyperlocomotion, latent
inhibition (LI) disruption, and prepulse inhibition deficits,19-21
which are behavioral abnormalities related to schizophrenia.
Methods
Animals
A total of 72 C57BL/6 male mice (2 months old) were
obtained from Universidade Federal de Pelotas and
maintained under controlled environmental conditions
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(reversed 12-h light/dark cycle with lights on at 7:00 a.m.
and constant temperature of 2261oC) with free access
to food and water. All procedures were approved by the
ethics committee of Hospital de Clı´nicas de Porto Alegre
(approval no. 13-0457), and were in agreement with the
principles applicable to the care and use of laboratory
animals.22 All efforts were made to minimize the number of
animals used and their suffering.
Drugs
NAC and D-amphetamine were purchased from Sigma-
Aldrich (St. Louis, MO, USA). All drugs were dissolved in
saline (0.9% NaCl). Solutions were freshly prepared and
injected intraperitoneally (i.p.) at final volumes of 5 mL/kg.
Amphetamine sensitization protocol
The sensitization protocol was based on the work of
Tenn et al.20 To increase the translational value of the
approach, this model is designed to mimic the prodromal
state of schizophrenia, and treatment start is delayed
until the second week to mimic early intervention. Animals
were randomly assigned across four groups, as depicted
in Figure 1. Injections were administered three times per
week over 3 weeks. Amphetamine doses were progres-
sively increased from 1 to 3 mg/kg from the first to the
third week. NAC (60 mg/kg) was given immediately before
saline or amphetamine during the second and third weeks.
Animals were returned to their home cages immediately
after the injections. Behavioral tests were performed in the
same animals after a 4-week washout starting after the last
amphetamine administration. NAC dose was based on
a previous study of ours showing that 60 mg/kg NAC
prevents increased sensitivity to amphetamine in social
isolation-reared mice.23
Latent inhibition (LI)
LI was assessed in a conditioned active avoidance pro-
cedure using a two-way shuttle box (Insight Equipamentos
Cientı´ficos, Ribeira˜o Preto, Brazil). In the first phase of the
test, animals from each of the four treatment groups were
allocated to a preexposure (PE) condition: conditioned
stimulus (CS)-PE or non-preexposure (NPE). The PE
subjects were placed in the apparatus and presented with
100 discrete exposures to a 5-s burst of white noise
(85 dBA), with a random interstimulus interval of 40615 s.
The NPE subjects were placed in the apparatus for
an equivalent period without any stimulus presentation.
On conditioning day (24 h later), all subjects received a
total of 100 avoidance trials presented with an intertrial
interval of 40615 s; each trial began with the onset of the
noise (CS). If the animal shuttled within 5 s of CS onset,
the CS was terminated and the animal avoided the
electric shock (unconditioned stimulus [US]) on that trial.
Avoidance failure led to an electric foot shock (0.3 mA)
presented in conjunction with the CS that could last for a
maximum of 2 s but could be terminated by a shuttle
response during this period (i.e., an escape response).
Conditioned avoidance learning was indexed as the mean
number of avoidance responses recorded on successive
blocks of 10 trials.
Locomotion
A week after LI, animals were subjected to an amphetamine
challenge (2 mg/kg, i.p.) in an open-field arena to assess
locomotor activity. The apparatus consisted of four identical
square arenas (4040 40 cm) located in a testing room
under dim diffused light. A webcam connected to a com-
puter was mounted directly above the four arenas, and the
videos were analyzed with ANY-Maze tracking software
(Stoelting Co., Wood Dale, IL, USA). The animals were
injected i.p. with vehicle solution and immediately placed in
the apparatus to measure basal locomotor activity for
30 min; subsequently, they were treated with amphetamine
and immediately returned to the same arena, where the
locomotor response was monitored for 90 min.
Statistics
Data were analyzed using ANOVA. Fisher’s least significant
difference (LSD) post-hoc tests were used whenever signif-
icant interactions were obtained by the initial ANOVAs.
Statistical significance was set at p o 0.05.
Figure 1 Experimental design. Drugs were administered intraperitoneally three times a week for 3 weeks. Amphetamine
(AMPH) doses were increased weekly (1 to 3 mg/kg). N-acetylcysteine (NAC, 60 mg/kg) or saline (SAL) was given immediately
before saline or amphetamine during the second and third weeks. Animals were returned to their home cages after injections.
Behavioral tests started after a 4-week washout. Animals were assigned to the following experimental groups: SAL/SAL,
NAC/SAL, SAL/AMPH, or NAC/AMPH.
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Results
Figure 2 shows the effects of amphetamine sensitization
and NAC on LI. A LI effect was observed in control (SAL/
SAL) animals (Figure 2A); consistent with previous studies,
the sensitization protocol led to a disruption in LI (Figure 2C).
NAC abolished the LI effect in the control group (Figure 2B)
and failed to counteract the sensitization-induced LI disruption
(Figure 2D); 2 10 (PE condition  10-trial blocks) ANOVAs
restricted to each of the four experimental groups revealed a
significant PEmain effect only for the SAL/SAL group (F1,11 =
13.9, p o 0.01).
Figure 3 shows that N-acetylcysteine (NAC) attenuated
the hyperlocomotion induced by the sensitization protocol
(pretreatment  bins interaction: F11,429 = 16.5, po 0.0001),
without affecting basal locomotor activity.
Figure 2 Effects of amphetamine (AMPH) sensitization and N-acetylcysteine (NAC) on latent inhibition (LI). LI was observed in
the control group (saline – SAL/SAL) (A), and disrupted by amphetamine (SAL/AMPH) (C). NAC abolished LI in control animals
(NAC/SAL) (B) and failed to prevent amphetamine sensitization-induced disruption of LI (NAC/AMPH) (D). Mean + standard
error, n=7-9. NPE = non-preexposed; PE = preexposed. * p o 0.01, concerning main effect of preexposure condition.
Figure 3 Effects of amphetamine sensitization and N-acetylcysteine (NAC) on locomotion. NAC partially prevented the
increased locomotion induced by amphetamine (AMPH) challenge in sensitized animals. Mean + standard error, n=10-11.
* p o 0.05 compared to saline (SAL/SAL); w p o 0.05 compared to NAC/AMPH.
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Discussion
In the present study, we showed that mice can be
sensitized by treatment with amphetamine in an escalat-
ing dose schedule, as measured by the magnified loco-
motor response to amphetamine challenge after 4 weeks
of withdrawal. NAC partially counteracted the neuroadap-
tive changes that determine long-term sensitization to the
effect of amphetamine on locomotion. However, NAC failed
to prevent amphetamine-induced LI disruption. Of note,
NAC disrupted LI in non-sensitized (control) animals.
Glutamate pathways may contribute to the neurochemical
mechanisms that underlie sensitization. Psychostimulants
enhance glutamate release in the nucleus accumbens,24
activating N-methyl-D-aspartate (NMDA) receptors; the
resulting increase in intracellular calcium concentration is a
prerequisite for sensitization.25,26 NAC, by activating the
cystine-glutamate antiporter, increases extrasynaptic gluta-
mate, resulting in stimulation of metabotropic glutamate
receptors 2/3 (mGluR2/3), with a consequent decrease in
synaptic glutamate release.15,16,27 This mechanism may
underlie the counteracting effects of NAC on amphetamine
sensitization, especially since microdialysis studies have
shown that NAC prevents the increase in glutamate levels
induced by cocaine and phencyclidine, as well as the
increased locomotion induced by these drugs.16,28
Several studies have reported protective effects of NAC
against the neurotoxic effects of psychostimulants.29-32
These neurotoxic effects are attained by continuous delivery
or multiple injections of amphetamine at high doses; the
maintenance of elevated amphetamine levels in the brain for
several days damages dopamine terminals in the striatum,
a process accompanied by increased oxidative stress.33,34
The antioxidant properties of NAC are likely to play an
important protective role in the neurotoxic paradigm.33-35
The intermittent administration (three times a week) and
escalating low-dose amphetamine regimen used herein
do not lead to the pronounced neurotoxic effects observed
with successive high amphetamine doses or continuous
delivery.7,36
Repeated amphetamine administration protocols are
also used to model bipolar disorder and drug abuse.
Modeling mania, Valvassori et al.37 reported that NAC
(20 mg/kg three times a day) did not prevent the hyper-
activity induced by 1 week of daily amphetamine in rats.
Investigating the effects of NAC on methamphetamine
abuse, Fukami et al.29 showed that NAC (100 mg/kg)
prevented the behavioral sensitization produced by five
daily injections of methamphetamine in rats. The amphe-
tamine regimen used in this study, which adds dose
progression to the mere repetition of amphetamine used
in other protocols, leads to behavioral and neurochemical
alterations observed in patients with schizophrenia and
at-risk subjects.19-21 In the present study, NAC treatment
was initiated a week after amphetamine exposure, and dif-
ferent protective results might have been obtained if NAC
treatment had been initiated along with amphetamine.
LI, which is disrupted in patients with schizophrenia,
is a measure of selective associative learning in which
repeated exposure to a non-reinforced stimulus delays
subsequent conditioning with that stimulus.38,39 NAC did
not prevent the amphetamine sensitization-induced disrup-
tion of LI, and in fact disrupted it in non-sensitized mice.
Several drugs disrupt LI, including antipsychotics,40-43 and
this NAC-induced LI disruption remains to be examined.
The use of different amphetamine schedules suggests that
deficits in information processing are mediated by different
neuronal mechanisms than those underlying locomotor
sensitization.8 Different neurochemical bases for these two
phenomena would be consistent with the differential effects
of NAC on locomotor sensitization and LI.
Limitations of this study include the use of only one
dose of NAC and the absence of associated neurochem-
ical measures. Although modulation of glutamate release
might be implicated in the effects of NAC on the behavioral
parameters here assessed, the precise mechanism remains
to be elucidated. Nevertheless, this study advances the
hypothesis that NAC may be advantageous for preventing
the neurochemical changes that are thought to characterize
the prodromal state in patients at risk of developing full-
blown schizophrenia.
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